Cancer Treatments

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of $1.25 billion. The consideration...

Merck & Co Inc (NYSE:MRK) on Thursday said the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. The study also met a secondary...

Bayer AG (OTC:BAYRY) reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago. The company reported: Adjusted earnings of 65 cents, beating the consensus of 38 cents. Sales reached $14.45 billion (13.74 billion...

While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. Today, a molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed NV...

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detection test Cologuard. This is a patient-friendly, non-invasive stool-based DNA test that users can...

Pfizer Inc (NYSE: PFE) is in early discussions to purchase biotechnology company Seagen Inc (NASDAQ: SGEN), The Wall Street Journal reported late on Sunday, citing people familiar with the matter. The deal would reportedly be valued at more than $30 billion and will help Pfizer...

Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company focused on developing and commercializing novel oncology products that target tumor microenvironment, gained more than 10 percent Thursday morning. Investors and traders were buying Halozyme's stock after the company...